.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical follow-up of 11 months, individuals with metastatic stomach tumors that obtained biomarker-matched treatments based on flowing lump DNA profiling revealed a higher medical advantage than those acquiring unequaled therapy.